MedPath

Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG)

Not Applicable
Recruiting
Conditions
Stent Migration
GastroEsophageal Cancer
Interventions
Device: Gastroesophageal stent placement
Registration Number
NCT05431738
Lead Sponsor
Société Française d'Endoscopie Digestive
Brief Summary

The aim of this prospective, controlled, randomized, multicentre, single-blind study is to compare the rate of intragastric migration of 2 types of esophageal stents with and without an anti-migration device placed for locally advanced or metastatic malignant stenosis of the gastroesophageal junction.

Detailed Description

In order to reduce the rate of spontaneous intragastric migration of esophageal stent placed for gastroesophageal junction tumor, anti-migration device has been developed. Pilot studies suggest the absence of morbidity of this device, but no comparative study has been conducted to confirm the interest of this anti-migration device.

The aim of this study is to compare the rate of intragastric migration of 2 types of esophageal stents with and without an anti-migration device placed for locally advanced or metastatic malignant stenosis of the gastroesophageal junction.

* Main objective: To evaluate the rate of intragastric migration of 2 types of esophageal stents (one with and the second without anti-migration device) placed for malignant stenosis of the gastroesophageal junction.

* Secondary objective(s):

* Degraded migration rate (M3 and M6) if patient alive, and duration of survival without dysphagia

* Comparison of the morbidity of these two stents

* Comparison of the effectiveness of these two stents on dysphagia and reflux

* Clinical and technical failure rate of these two stents

This is a prospective, controlled, randomized, multicentre, single-blind study.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
180
Inclusion Criteria
  1. Patient of both sexes aged 18 or over.
  2. Patient admitted to one of the investigation centers for dysphagia due to tumoral stenosis of the gastroesophageal junction, locally advanced or metastatic.
  3. Patient ASA 1, ASA 2, ASA 3
  4. Absence of participation in another clinical study
  5. Signed Informed Consent
  6. Patients benefiting from the social security system.
Exclusion Criteria
  1. Patient referred for stenosis by extrinsic compression by an extra digestive mass
  2. Patients with contraindications relating to the procedures essential for the introduction of a stent
  3. Mediastinal radiotherapy or esophageal surgery history
  4. Patient under 18 or over 90
  5. Patient ASA 4, ASA 5
  6. Pregnant Woman
  7. Patient unable to give personal consent
  8. Absence of signed informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
STENT WITH ANTI-MIGRATION DEVICEGastroesophageal stent placementPlacement of a gastroesophageal stent with anti-migration device : Ella®, Leufen, Novatech
STENT WITHOUT ANTI-MIGRATION DEVICEGastroesophageal stent placementPlacement of a gastroesophageal stent without anti-migration device : Hanarostent® ECW, Life Partners Europe
Primary Outcome Measures
NameTimeMethod
Stent Intragastric migration rate at M11 month

Stent Intragastric migration rate at M1 confirmed on radiography or CT

Secondary Outcome Measures
NameTimeMethod
Dysphagia recurrence at M33 months

Dysphagia evaluation in 5 stages (Atkinson score) at M3 0 - no dysphagia

1. - Clinging to the swallowing of solids

2. - Semi-liquid feeding possible

3. - Liquid feeding possible

4. - Aphagia (need for parenteral nutrition)

Gastroesophageal reflux disease (GERD) after stent placement1 month

Gastroesophageal reflux disease with the Reflux Disease Questionnaire (RDQ) score. The Reflux Disease Questionnaire a 12-item self-administered questionnaire, was designed to assess the frequency and severity of heartburn, regurgitation, and dyspeptic complaints and to facilitate the diagnosis of GERD. Minimum 12 : better outcome Maximum 72 : worse outcome

Stent placement complication : hemorrhage7 days

Necessity of blood transfusion and/or endoscopic management

Clinical success rate of stent placement on dysphagia3 days

Medical success rate of stent placement under digestive endoscopy on dysphagia (dysphagia resorption after endoscopy)

Stent Intragastric migration rate at M33 months

Stent Intragastric migration rate at M3 confirmed on radiography or CT

Dysphagia-free survival time3 years

Dysphagia-free survival time at the end of the study

Stent Intragastric migration rate at M66 months

Stent Intragastric migration rate at M6 confirmed on radiography or CT

Dysphagia recurrence at M11 month

Dysphagia evaluation in 5 stages (Atkinson score) at M1 0 - no dysphagia

1. - Clinging to the swallowing of solids

2. - Semi-liquid feeding possible

3. - Liquid feeding possible

4. - Aphagia (need for parenteral nutrition)

Dysphagia recurrence at M66 months

Dysphagia evaluation in 5 stages (Atkinson score) at M6 0 - no dysphagia

1. - Clinging to the swallowing of solids

2. - Semi-liquid feeding possible

3. - Liquid feeding possible

4. - Aphagia (need for parenteral nutrition)

Technical success rate of stent placement1 day

Technical success rate of stent placement under digestive endoscopy defined by good progression of contrast through the stent into the gastric cavity after stent placement

Stent placement complication : pain7 days

Need for opioid treatment for more than 48 hours after stent placement or removal of the stent because of pain

Stent placement complication : pneumoperitoneum1 day

Pneumoperitoneum diagnosed by CT in case of abnormal pain within hours of stent placement

Trial Locations

Locations (1)

French Society of Digestive Endoscopy

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath